The clinicians should, therefore, consider testing CSF GFAP-Abs in cases of atypical CIDP-like diseases associated with CNS symptoms and CSF pleocytosis. This evidence concerns the gene GFAP and chronic inflammatory demyelinating polyradiculoneuropathy.